Autolus Therapeutics AUTL Stock
Autolus Therapeutics Price Chart
Autolus Therapeutics AUTL Financial and Trading Overview
| Autolus Therapeutics stock price | 1.78 USD |
| Previous Close | 1.85 USD |
| Open | 1.85 USD |
| Bid | 1.75 USD x 600 |
| Ask | 2.26 USD x 200 |
| Day's Range | 1.76 - 1.88 USD |
| 52 Week Range | 1.18 - 2.58 USD |
| Volume | 1.81M USD |
| Avg. Volume | 2.06M USD |
| Market Cap | 473.77M USD |
| Beta (5Y Monthly) | 2.094 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.06 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.73 USD |
AUTL Valuation Measures
| Enterprise Value | 639.95M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.840637 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.0358577 |
| Price/Book (mrq) | 6.33452 |
| Enterprise Value/Revenue | 5.451 |
| Enterprise Value/EBITDA | -2.705 |
Trading Information
Autolus Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.094 |
| 52-Week Change | 14.90% |
| S&P500 52-Week Change | 14.15% |
| 52 Week High | 2.58 USD |
| 52 Week Low | 1.18 USD |
| 50-Day Moving Average | 2.02 USD |
| 200-Day Moving Average | 1.67 USD |
AUTL Share Statistics
| Avg. Volume (3 month) | 2.06M USD |
| Avg. Daily Volume (10-Days) | 1.49M USD |
| Shares Outstanding | 266.16M |
| Float | 102.92M |
| Short Ratio | 3.86 |
| % Held by Insiders | 18.08% |
| % Held by Institutions | 63.42% |
| Shares Short | 8.33M |
| Short % of Float | 4.82% |
| Short % of Shares Outstanding | 3.13% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -238.65% |
| Operating Margin (ttm) | -95.94% |
| Gross Margin | -74.60% |
| EBITDA Margin | -201.52% |
Management Effectiveness
| Return on Assets (ttm) | -25.43% |
| Return on Equity (ttm) | -132.99% |
Income Statement
| Revenue (ttm) | 117.39M USD |
| Revenue Per Share (ttm) | 0.44 USD |
| Quarterly Revenue Growth (yoy) | 118.39% |
| Gross Profit (ttm) | -87577000 USD |
| EBITDA | -236571008 USD |
| Net Income Avi to Common (ttm) | -280156000 USD |
| Diluted EPS (ttm) | -1.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 201.63M USD |
| Total Cash Per Share (mrq) | 0.76 USD |
| Total Debt (mrq) | 367.81M USD |
| Total Debt/Equity (mrq) | 491.47 USD |
| Current Ratio (mrq) | 4.886 |
| Book Value Per Share (mrq) | 0.281 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -225608000 USD |
| Levered Free Cash Flow (ttm) | -201190000 USD |
Profile of Autolus Therapeutics
| Country | United States |
| State | N/A |
| City | London |
| Address | The Mediaworks |
| ZIP | W12 7FP |
| Phone | 44 20 3829 6230 |
| Website | https://www.autolus.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 752 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Q&A For Autolus Therapeutics Stock
What is a current AUTL stock price?
Autolus Therapeutics AUTL stock price today per share is 1.78 USD.
How to purchase Autolus Therapeutics stock?
You can buy AUTL shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Autolus Therapeutics?
The stock symbol or ticker of Autolus Therapeutics is AUTL.
Which industry does the Autolus Therapeutics company belong to?
The Autolus Therapeutics industry is Biotechnology.
How many shares does Autolus Therapeutics have in circulation?
The max supply of Autolus Therapeutics shares is 266.16M.
What is Autolus Therapeutics Price to Earnings Ratio (PE Ratio)?
Autolus Therapeutics PE Ratio is now.
What was Autolus Therapeutics earnings per share over the trailing 12 months (TTM)?
Autolus Therapeutics EPS is -1.06 USD over the trailing 12 months.
Which sector does the Autolus Therapeutics company belong to?
The Autolus Therapeutics sector is Healthcare.
Autolus Therapeutics AUTL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27190.86 USD — |
+1.19
|
6.86B USD — | 27112.24 USD — | 27353.68 USD — | — - | 6.86B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13380.95 USD — |
+1.21
|
— — | 13341.63 USD — | 13459.93 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6947.64 USD — |
-0.26
|
— — | 6917.55 USD — | 6998.5 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1302.61 USD — |
-0.29
|
— — | 1298.55 USD — | 1311.62 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
